Ionis Pharmaceuticals (IONS) Expected to Announce Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is projected to announce its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.8471) per share and revenue of $197.4520 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:30 AM ET.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, February 25th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). The business had revenue of $203.33 million for the quarter, compared to the consensus estimate of $156.07 million. Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.The company’s revenue for the quarter was down 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Price Performance

NASDAQ IONS opened at $74.78 on Wednesday. The company has a market cap of $12.35 billion, a PE ratio of -30.65 and a beta of 0.40. Ionis Pharmaceuticals has a 52 week low of $28.46 and a 52 week high of $86.74. The company has a quick ratio of 3.81, a current ratio of 3.83 and a debt-to-equity ratio of 2.76. The firm’s 50-day simple moving average is $76.46 and its two-hundred day simple moving average is $77.17.

Insider Activity

In other news, EVP Shannon L. Devers sold 6,193 shares of the company’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $74.05, for a total transaction of $458,591.65. Following the sale, the executive vice president directly owned 16,348 shares in the company, valued at $1,210,569.40. This represents a 27.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Eugene Schneider sold 5,812 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $70.97, for a total value of $412,477.64. Following the sale, the executive vice president owned 63,890 shares in the company, valued at approximately $4,534,273.30. This represents a 8.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 868,132 shares of company stock valued at $67,343,911. 2.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Axxcess Wealth Management LLC bought a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $228,000. Corient Private Wealth LLC increased its position in shares of Ionis Pharmaceuticals by 3,161.5% during the fourth quarter. Corient Private Wealth LLC now owns 214,936 shares of the company’s stock valued at $17,004,000 after buying an additional 208,346 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of Ionis Pharmaceuticals by 48.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 5,554 shares of the company’s stock valued at $439,000 after buying an additional 1,807 shares during the period. Mackenzie Financial Corp increased its position in shares of Ionis Pharmaceuticals by 8.4% during the fourth quarter. Mackenzie Financial Corp now owns 3,891 shares of the company’s stock valued at $307,000 after buying an additional 303 shares during the period. Finally, ADAR1 Capital Management LLC increased its position in shares of Ionis Pharmaceuticals by 9.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 147,130 shares of the company’s stock valued at $11,639,000 after buying an additional 13,312 shares during the period. 93.86% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IONS has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Needham & Company LLC upped their price objective on shares of Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Wall Street Zen downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. Finally, Leerink Partners upped their price objective on shares of Ionis Pharmaceuticals from $102.00 to $104.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Eighteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $96.90.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.